Search results
BioLineRx reports positive pancreatic cancer trial results By Investing.com
Investing.com· 2 days agoBioLineRx Ltd. (NASDAQ: BLRX), a biopharmaceutical company, announced encouraging results from the...
HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated...
FOX21 Colorado Springs· 18 hours ago82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n=2/10) who received placebo, and patients ...
Inhibiting a metabolic pathway provides new approach to Epstein-Barr virus and resulting diseases
Medical Xpress· 2 days agoThe Epstein-Barr virus can cause a spectrum of diseases, including a range of cancers. Emerging data...
Treating Scalp Inflammation Can Reverse Hair Loss — Experts Share the Easy + Soothing Remedies
Woman's World via Yahoo News· 4 days agoHair restoration For very advanced cases, in which scarring of the follicle causes permanent hair...
Rutgers Cancer Institute and RWJBarnabas Health Set to Unveil Extensive, New Cancer Research...
FOX 4 Kansas City· 2 days agoClinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...
Sylvester Research Shows New Treatment May Enable | Newswise
Newswise· 3 days agoA new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a ...
Roche Holding AG (OTCMKTS:RHHBY) Receives $40.00 Consensus Target Price from Brokerages
ETF DAILY NEWS· 1 day agoRoche Holding AG (OTCMKTS:RHHBY – Get Free Report) has earned an average rating of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat reports. One analyst has ...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
KSAN - KLST San Angelo· 19 hours agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European ...
Artificially transplanted mitochondria in endothelial cells promote mitophagy - Nature Reviews...
Nature· 5 days agoA study in Nature describes a single-cell-type strategy for vascular cell therapies that involves the artificial transplantation of mitochondria to endothelial cells, which ...
Southwest Transplant Alliance Announces Partnership with Medi-Ops to Utilize Technology-Enabled...
KPVI· 4 days agoThe organ procurement and transplantation process is intricate and utilizes many different modes of...